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Background: Medication-related problems are a serious concern in Australian primary care. Pharmacist
interventions have been shown to be effective in identifying and resolving these problems. Collaborative general
practitioner-pharmacist services currently available in Australia are limited and underused. Limitations include
geographical isolation of pharmacists and lack of communication and access to patient information. Co-location of
pharmacists within the general practice clinics is a possible solution. There have been no studies in the Australian
setting exploring the role of pharmacists within general practice clinics.
The aim of this study is to develop and test a multifaceted practice pharmacist role in primary care practices to
improve the quality use of medicines by patients and clinic staff.
Methods/design: This is a multi-centre, prospective intervention study with a pre-post design and a qualitative
component. A practice pharmacist will be located in each of two clinics and provide short and long patient
consultations, drug information services and quality assurance activities. Patients receiving long consultation with a
pharmacist will be followed up at 3 and 6 months. Based on sample size calculations, at least 50 patients will be
recruited for long patient consultations across both sites. Outcome measures include the number, type and severity
of medication-related problems identified and resolved; medication adherence; and patient satisfaction. Brief
structured interviews will be conducted with patients participating in the study to evaluate their experiences with
the service. Staff collaboration and satisfaction with the service will be assessed.
Discussion: This intervention has the potential to optimise medication use in primary care clinics leading to better
health outcomes. This study will provide data about the effectiveness of the proposed model for pharmacist
involvement in Australian general practice clinics, that will be useful to guide further research and development in
this area.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12612000742875
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Medication misadventure remains a serious concern in
Australian primary care [1,2]. It is estimated that one
in 10 patients who visit their general practitioner (GP)
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reproduction in any medium, provided the orwith 8% requiring hospitalization [1]. Approximately one
in four of these are preventable. These data are consist-
ent with studies from other countries. For example,
a recent UK study revealed that one in 20 prescription
items in general practice contained an error, affecting
1 in 8 patients [3]. Poor communication has been identi-
fied as a major contributing factor towards MRPs, [2]
highlighting the need for greater collaboration between
GPs, pharmacists and other primary health professionals
to ensure optimal patient care.
Collaborative medication reviews, undertaken by phar-
macists and GPs, have been successful in identifying and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ity of prescribing, and optimizing drug use and costs
[4,5]. These collaborative services, however, are currently
limited and underused due to factors including geo-
graphical isolation, limited access to patient medical
records, a lack of time for team activities and a health
policy that is not conducive to such collaborative arrange-
ments [6]. Additionally, communication between GPs
and pharmacists in the community setting is sporadic and
reactive, risking fragmentation of patient care [7].
A possible solution to these problems is the integration
of pharmacists into general practices and primary health-
care clinics. In countries such as the United Kingdom,
Canada and the United States, practice pharmacists work
in close collaboration with GPs (family physicians) to
undertake a range of clinical and administrative tasks
[8,9]. Some studies suggest the implementation of these
roles can result in improved medication use and health
outcomes and reduced health service use and cost [10-12].
Co-location has also been shown to enable greater com-
munication and cooperation between health professionals,
and strengthen the primary health care team [13].
The aim of this study is to develop and test a multifa-
ceted practice pharmacist role in primary care practices
in Australia to improve the quality use of medicines by
patients and clinic staff.
Methods/design
This is a multi-centre, prospective intervention study
with a pre-post design and a qualitative component,
involving two general practice (primary care) clinics in
Melbourne, Australia.
Recruitment of practices and pharmacists
Primary care clinics will be invited to participate through
advertisements and consultation with the Victorian
Divisions of General Practice and key informants in
Melbourne, Australia. Primary care practices that have
the space to accommodate a co-located pharmacist will
be targeted. An independent practice pharmacist with
significant clinical experience and accreditation to con-
duct Government funded collaborative Home Medicines
Reviews (HMRs) will be identified for each clinic
through advertisements and key informants.
Intervention
The intervention will consist of a multi-faceted, collabora-
tive service targeting patients and practice staff. A practice
pharmacist will be co-located in each of the study clinics
for at least eight hours per week for six months. The prac-
tice pharmacist will undertake the following tasks:
1. Long patient consultations
2. Short patient consultations3. Drug information and education service for clinic
staff; and
4. Quality assurance activities
Long patient consultation
Recruitment of participants
Participants for the long patient consultations will be
practice patients who may be at an increased risk of
MRPs [14].
Inclusion criteria
 Using five or more medicines
 Using one or more medicines that require
therapeutic drug monitoring (e.g. warfarin,
phenytoin, lithium)
 Using medicines for three or more medical
problems
 Have had a recent unplanned hospital admission/
emergency department visit
 Having other reason(s) for being at risk of
medication misadventure (e.g. adherence issues,
language barriers, multiple prescribers)
Exclusion criteria
 Have had a HMR in the previous 12 months with
no subsequent significant change in clinical status or
medication regimen
 Are unable to provide written informed consent
 Are under 18 years of age
 Are unavailable for follow up for six months after
recruitment
Patients meeting one or more of the eligibility criteria
will be considered for referral to the study by their gen-
eral practitioner or clinic staff. Those patients who are
referred to the study will be provided with an introduc-
tory letter and plain language statement in person during
their clinic visit. Patients will be asked by the GP/clinic
staff if they are willing to be contacted by the research
team. If patients agree, the GP/clinic staff will provide
the research team with the patient’s contact details.
The research assistant will contact patients who agreed
to provide their contact details. Suitable and willing par-
ticipants will be recruited by obtaining initial verbal con-
sent. Written consent will be obtained at the time of the
appointment with the practice pharmacist.
Baseline data collection
Baseline data will be collected by the research assistant
using a structured questionnaire, either in person (at the
clinic or the person’s home) or by telephone, and will
include demographic information (age, sex, ethnicity,
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etc.), health information (general health, health service
use, health literacy [15] etc.), and medicines information
(medication risk [14] adherence [16,17] etc.). The
research assistant will then organize for the participant
to meet the practice pharmacist for a long consultation.
Long patient consultation process
All participants will receive a 30–60 minute consultation
with the pharmacist in a private room at the clinic
(or a home visit if they prefer or are housebound) to per-
form a comprehensive medication review and identify
medication-related problems (MRPs). Prior to the con-
sultation, the pharmacist will discuss any health or
medication-related issues with the GP or clinic staff, if
needed. The pharmacist will also review participants’
general practice medical record (including progress
notes, medication lists and pathology results) and dis-
pensing histories if needed. The pharmacist will obtain
written informed consent from the participant. In
addition to reviewing the participant’s medication regi-
men, the pharmacist will assess medication adherence
and knowledge. The pharmacist will provide counseling
and education as needed on medication management
and the use of medication devices, and reinforce lifestyle
advice related to their health problems and medications.
The pharmacist may provide the participant with a
complete medication list and refer them to their com-
munity pharmacy for adherence aids (e.g. pill boxes,
administration aids), if needed. Additionally, referral
may be made to the GP or other health professionals as
required. After the consultation, the pharmacist will
write a short report outlining MRPs and recommenda-
tions, and provide this to the participant’s GP either
electronically (via secure email or directly into the prac-
tice’s electronic medical record) or as a paper-based re-
port, depending on the GP’s preference. The pharmacist
may update the medication history within the practice’s
medical record as needed. Following this, the pharmacist
will discuss any issues with the GP, other staff and com-
munity pharmacist, if needed. Case conferencing may be
organized where appropriate.
Monitoring and follow up
Participants will be followed up by the research assistant at
three and six months either in the clinic or by telephone
to collect data about implementation of pharmacist
recommendations, resolution of MRPs identified by the
practice pharmacist, participant’s medication adherence
and participant’s general health and wellbeing.
Sample size
Based on an expected average number of 2.5 MRPs per
participant at baseline, an expected average reductionof 1 MRP (i.e. 40%) per participant with a within-
participant standard deviation of 2.1 MRPs (assuming a
correlation coefficient of 0.5), [18,19] a power of 80%
and a two-tailed alpha of 0.05, the required sample size
is 37 participants. Allowing for a dropout/loss to follow-
up rate of 25%, at least 50 participants will be recruited.
This was calculated using PS Power and Sample Size
Calculations (Version 3.0, Dupont & Plummer, 2009).
Short patient consultation
Patients with potential medication issues (e.g. nonadher-
ence, newly prescribed medicines) who do not require
a comprehensive review of their complete medication
regimen may receive a short consultation with the
pharmacist. Data will be collected about these consulta-
tions, but the patients will not be consented for the
study (no personal or identifying data will be collected).
Referrals may be made by GPs or clinic staff, or patients
may self-refer. The short patient consultation will last
15–30 minutes and provides an opportunity for the
pharmacist to provide brief education and counseling on
specific needs or answer questions. Short patient consul-
tations will only be undertaken in the clinic. After the
consultation, the pharmacist will write brief notes dir-
ectly into the electronic medical record, and update
records as needed. Examples of services to be provided
in these consultations include: new medication counsel-
ing, adherence assessment, assessment of and education
on device technique (e.g. using asthma inhalers), and
provision of a medication list. Patient satisfaction will be
assessed by an anonymous questionnaire to be given to
each patient by the pharmacist along with a reply-paid
envelope addressed to the researchers.
Drug information and education service
The practice pharmacist will provide a drug information
service for practice staff. Queries can be made to the
pharmacist in person, by telephone or via email. All
queries (and responses) will be documented by the
pharmacist. Practice staff will also be invited to attend
pharmacist-led group education sessions targeting topics
relevant to them (e.g. new therapy or treatment proto-
cols), and a weekly drug information newsletter may also
be produced by the pharmacist and provided to staff.
Quality assurance activities
The practice pharmacists will undertake a Drug Use and
Evaluation (DUE) program in the clinic. The pharma-
cists will review current prescribing patterns, evaluate
these against current best practice guidelines, and imple-
ment an intervention to address deficiencies identified
using established DUE methodology [20]. A pharma-
cotherapeutic area of concern or importance will be
identified by the pharmacist in conjunction with the GPs
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the research team, will decide upon audit criteria and
measurement instruments will be derived from pub-
lished clinical practice guidelines. The pharmacist will
collect and evaluate data relevant to medication use
in this area by retrospectively reviewing electronic med-
ical records. Confidentiality of data will be ensured by
de-identifying all information collected. Results and
feedback will be provided to staff. Multifaceted strategies
to improve the quality of prescribing in the selected area
will be developed and implemented by the interdisciplin-
ary team, and re-evaluated at the end of the study
period. Patients will not be recruited or consented
to this part of the study, and no identifying data will
be collected.
Monitoring and follow up
Actions arising from the DUE program (e.g. develop-
ment and implementation of clinical guidelines, criteria,
treatment protocols, education programs) will be assessed
for effectiveness after six months by repeating the pre-
scribing audit to complete the DUE cycle [20].
Outcomes
Outcomes of long patient consultations
Medication-related problems The primary outcome
of the long consultations will be the number of MRPs
identified by practice pharmacists and the number of
identified MRPs that are resolved as a result of the phar-
macists’ interventions. The number of MRPs, number of
recommendations made by the pharmacists and the
number of recommendations accepted/implemented
will be recorded and determined by chart audit and/or
patient interview, conducted by a research assistant. The
types of problems will be categorized by the research
team according to the criteria described by Strand et al
[21]. The severity of the MRPs and the likely conse-
quences if they had not been addressed will be assessed
by an expert panel using a risk classification system [22].
Medication adherence Participants’ medication adher-
ence will be measured using two methods – the Morisky
Scale [16] and the Tool for Adherence Behaviour
Screening (TABS) [17] at baseline, three and six months.
The Morisky Scale is a validated 4-item scale that asks
patients four ‘yes/no’ questions regarding patterns of
medication use. A patient is considered non-adherent if
they answer ‘yes’ to any of the questions. The TABS
is a validated and reliable sub-scale of the Beliefs and
Behaviour Questionnaire (BBQ). The TABS consists of
two, 4-item subscales for adherence and non-adherence.
It screens for medication non-adherence that is both
intentional and unintentional and assesses the respondent’sagreement with a series of statements that are scored on
a five-point Likert scale. The total score for 'nonadher-
ence' will be subtracted from that of 'adherence'; a differ-
ential of ≥15 will be considered as good adherence and
≤14 will be considered as suboptimal adherence [23].
General health Patient general health and wellbeing,
including use of health services, will be assessed via
patient self-report at baseline, three and six months.
Other outcomes
Satisfaction
Patient satisfaction with the practice pharmacist will be
determined by a structured, satisfaction questionnaire
adapted from a previously validated patient satisfaction
survey by Baker regarding physician consultations
[24,25]. The questionnaire will be anonymous and pro-
vided at the end of any interaction with the pharmacist
(including long patient consultations and short patient
consultations). Participants will be requested to com-
plete and return the questionnaire before they leave the
practice or at their earliest convenience, using a reply-
paid envelope.
Quality of prescribing and medication use
The effectiveness of the DUE program will be assessed
by re-evaluating medication use in the targeted popula-
tion at the end of the study and comparing this to base-
line data.
Drug information queries
The number of drug information queries made and
answered, the type of queries made and by whom, will
be evaluated at six months.
Short patient consultations
General information regarding the nature of the short
consultations will be recorded, including the reason for
referral, type of service provided and average time spent.
Experiences and feedback
The views of a sample of stakeholders on their experi-
ences with this new service will be explored using inter-
views and/or focus groups at the study’s conclusion.
Patients and staff will have the opportunity to share
their thoughts on the perceived benefits and challenges
of the service and how it could be improved and devel-
oped further.
Data analysis
Data will be entered into the Statistical Package for
Social Sciences (SPSS) for Windows Version 19.0 (IBM,
New York, USA) and analyzed using standard descrip-
tive methods. Bivariate analysis will be performed
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t-tests for continuous variables, McNemar chi-square
tests for categorical variables, and Wilcoxon matched-
pairs signed-ranks tests for ordinal variables. Compari-
sons between practices may be done using repeated
measures analysis of variance (ANOVA). Binary logistic
regression may be performed to identify independent
predictors of having medication-related problems and
effects on adherence and other outcomes.
Qualitative data management will be facilitated using
NVivoW (Version 9, Qualitative Solutions & Research
International, Melbourne, Vic). Interview transcripts will
be read by two independent researchers and coded for
emergent themes. Any discrepancies will be discussed
and sorted in team meetings in the presence of a third
researcher. A framework approach may be utilized
whereby a thematic framework, based on a priori issues,
will be applied to the data [26]. This will allow data
to be easily indexed and charted, thus aiding subse-
quent interpretation.
Ethics
This study has been approved by the Monash University
Human Research Ethics Committee.
Discussion
To the best of our knowledge, this is the first study in
Australia to evaluate an interdisciplinary, multifaceted
practice pharmacist role to improve the quality use of
medicines by both patients and clinic staff. The compre-
hensive nature of this intervention aims to optimise
medicine use at several levels. Although the study will
be conducted with a pre-post design, subjects will serve
as their own controls, thus eliminating inter-subject vari-
ability and reducing confounding. Additionally, the study
will be conducted in more than one primary care clinic
allowing for inter-practice comparison and improving
external validity.
The study involves mixed methods to capture and
measure a variety of data to explain the impact of the
intervention. Additionally, a range of process, health,
medication management and humanistic outcomes will
be collected. By using both quantitative and qualitative
methods, a deeper exploration of the intervention can
occur. This will enable a more comprehensive explor-
ation of the various intricacies involved in both types
of settings, thus allowing identification of the optimal
models of pharmacist integration for various primary
care clinics.
Limitations
The before and after design, which lacks a concurrent
control group, may compromise the internal validity of
the study and limit the conclusions drawn from theresults. Non-random sampling means external validity is
also compromised. However, this design is the most suit-
able and practical given the nature of the intervention; a
controlled trial with randomization at the level of the
patient would be severely limited by contamination, and
a cluster randomized controlled trial would require mul-
tiple practices, which is not feasible in the context of
limited resources.
Conclusion
The integration and co-location of a practice pharmacist
into Australian primary healthcare clinics is uncommon
and has not been evaluated. This study will implement
and evaluate a new collaborative pharmacist role and
assess its effects on optimizing medication outcomes
at various levels. The study will provide useful data to
guide further research and development in this area.
Abbreviations
MRP: Medication-related Problem; GP: General Practitioner; HMR: Home
Medicines Review; DUE: Drug Use Evaluation; TABS: Tool for Adherence
Behaviour Screening; BBQ: Beliefs and Behaviour Questionnaire.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ET (PhD candidate) participated in the design of the trial, recruitment and
manuscript preparation, and has an ongoing role in carrying out the trial. JG,
RAE and KS participated in the design of the trial and study methodology,
and review of the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
The project is funded by the Windermere Foundation.
Author details
1Centre for Medicine Use and Safety, Faculty of Pharmacy and
Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC
3052, Australia. 2Pharmacy Department, Austin Health, Studley Rd,
Heidelberg, VIC 3084, Australia.
Received: 29 June 2012 Accepted: 29 July 2012
Published: 9 August 2012
References
1. Miller GC, Britth HC, Valenti L: Adverse drug events in general practice
patients in Australia. Med J Aust 2006, 184:321–324.
2. Bhasale AL, Miller GC, Reid SE, Britt HC: Analysing potential harm in
Australian general practice: an incident-monitoring study. Med J Aust
1998, 169:73–76.
3. Avery T, Barber N, Ghaleb M, Dean Franklin B, Armstrong S, Crowe S,
Dhillon S, Freyer A, Howard R, Pezzolesi C, et al: Investigating the
prevalence and causes of prescribing errors in general practice: the
PRACtICe study. Gen Med Council 2012.
4. Gilbert AL, Roughead EE, Beilby J, Mott K, Barratt JD: Collaborative
medication management services: improving patient care. Med J Aust
2002, 177:189–192.
5. Stafford L, Stafford A, Hughes J, Angley M, Bereznicki L, Peterson G:
Drug-related problems identified in post-discharge medication reviews
for patients taking warfarin. Int J Clin Pharm 2011, 33:621–626.
6. Edmunds J, Calnan MW: The reprofessionalisation of community
pharmacy? An exploration of attitudes to extended roles for community
pharmacists amongst pharmacists and General Practioners in the
United Kingdom. Soc Sci Med 2001, 53:943–955.
Tan et al. BMC Health Services Research 2012, 12:246 Page 6 of 6
http://www.biomedcentral.com/1472-6963/12/2467. Farris K, Cote I, Feeny D, Johnson J, Tsuyuki R, Brilliant S, Dieleman S:
Enhancing primary care for complex patients. Demonstration project
using multidisciplinary teams. Can Fam Physician 2004, 50:998–1003.
8. Silcock J, Raynor DKT, Petty D: The organisation and development of
primary care pharmacy in the United Kingdom. Health Policy 2004,
67:207–214.
9. American Society of Health-system Pharmacists: ASHP Statement on the
Pharmacist's Role in Primary Care. Am J Health-Sys Ph 1999, 56:1665–1667.
10. Dolovich L, Pottie K, Kaczorowski J, Farrell B, Austin Z, Rodriguez C, Gaebel
K, Sellors C: Integrating family medicine and pharmacy to advance
primary care therapeutics. Clin Pharmacol Ther 2008, 83:913–917.
11. Borenstein JE, Graber G, Saltiel E: Physician-Pharmacist Comanagement of
Hypertension: A Randomized, Comparative Trial. Pharmacotherapy 2003,
23:209–216.
12. Zermansky AG, Petty DR, Raynor DK, Freemantle N, Vail A, Lowe CJ:
Randomized controlled trial of clinical medication review by a
pharmacist of elderly patients receiving repeat prescriptions in general
practice. Brit Med J 2001, 6:1340–1343.
13. Farrell B, Pottie K, Woodend K, Yao V, Dolovich L, Kennie N, Sellors C: Shifts
in expectations: Evaluating physicians' perceptions as pharmacists
become integrated into family practice. J Interprof Care 2010, 24:80–89.
14. Barenholtz Levy H: Self-administered medication-risk questionnaire in an
elderly population. Ann Pharmacother 2003, 37:982–987.
15. Chew LD, Bradley KA, Boyko EJ: Brief questions to identify patients with
inadequate health literacy. Fam Med 2004, 36:588–594.
16. Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a
self-reported measure of medication adherence. Med Care
1986, 24:67–74.
17. George J, Mackinnon A, Kong DC, Stewart K: Development and validation
of the Beliefs and Behaviour Questionnaire (BBQ). Patient Educ Couns
2006, 64:50–60.
18. Sellors J, Kaczorowski J, Sellors C, Dolovich L, Woodward C, Willan A,
Goeree R, Cosby R, Trim K, Sebaldt R, et al: A randomized controlled trial
of a pharmacist consultation program for family physicians and their
elderly patients. Can Med Assoc Jl 2003, 169:17–22.
19. Soendergaard B, Kirkeby B, Dinsen C, Herborg H, Kjellberg J, Staehr P: Drug-
related problems in general practice: results from a development project
in Denmark. Pharm World Sci 2006, 28:61–64.
20. SHPA Committee of Specialty Practice in Drug Use Evaluation: SHPA
Standards of Practice for Drug Use Evaluation in Australian Hospitals.
J Pharm Pract and Res 2004, 34:220–223.
21. Strand LM, Morely PC, Cipolle RJ, Ramsey R, Lamsam GD: Drug-related
problems: their structure and function. Ann Pharmacother 1990,
24:1093–1097.
22. Elliott R, Woodward M: Assessment of risk associated with medication-
related problems in elderly outpatients. J Pharm Pract and Res 2009,
39:109–113.
23. Lau R, Stewart K, McNamara KP, Jackson SL, Hughes JD, Peterson GM,
Bortoletto DA, McDowell J, Bailey MJ, Hsueh A, George J: Evaluation of a
community pharmacy-based intervention for improving patient
adherence to antihypertensives: a randomized controlled trial. BMC
Health Serv Res 2010, 10:34.
24. Baker R: Development of a questionnaire to assess patients' satisfaction
with consultations in general practice. Br J Gen Pract 1990, 40:487–490.
25. Stewart DC, George J, Bond CM, Cunningham IT, Diack HL, McCaig DJ:
Exploring patients' perspectives of pharmacist supplementary
prescribing in Scotland. Pharm World Sci 2008, 30:892–897.
26. Pope C, Ziebland S, Mays N: Qualitative research in health care. Analysing
qualitative data. Brit Med J 2000, 320:114–116.
doi:10.1186/1472-6963-12-246
Cite this article as: Tan et al.: An exploration of the role of pharmacists
within general practice clinics: the protocol for the pharmacists in
practice study (PIPS). BMC Health Services Research 2012 12:246.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
